Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies  

作　　者：Rachel SJ Wong Rebecca JM Ong Joline SJ Lim 

机构地区：[1]Department of Haematology-Oncology,National University Cancer Institute,National University Hospital,Singapore 119228,Singapore [2]Yong Loo Lin School of Medicine,National University of Singapore,Singapore 119228,Singapore

出　　处：《Cancer Drug Resistance》2023年第4期768-787,共20页癌症耐药（英文）

基　　金：JSJ Lim is supported by the NMRC(NMRC/MOH/00414).All other authors have no funding to declare.

摘　　要：The use of immune checkpoint inhibitors(iCls)has increased exponentially in the past decade,although its progress specifically for breast cancer has been modest.The first U.S.Food and Drug Administration approval for ICl in breast cancer came in 2019,eight years after the first-ever approval of an ICl.At present,current indications for ICls are relevant only to a subset of patients with triple-negative breast cancer,or those displaying high microsatellite instability or deficiency in the mismatch repair protein pathway.With an increasing understanding of the limitations of using ICls,which stem from breast cancer being innately poorly immunogenic,as well as the presence of various intrinsic and acquired resistance pathways,ongoing trials are evaluating different combination therapies to overcome these barriers.In this review,we aim to describe the development timeline of ICls and resistance mechanisms limiting their utility,and summarise the available approaches and ongoing trials relevant to overcoming each resistance mechanism.

关 键 词：IMMUNOTHERAPY immune checkpoint inhibitors resistance mechanisms breast cancer 

分 类 号：R730.45[医药卫生—肿瘤]